FDA称已就Corcept被拒库欣综合征药物问题早期做出解释。
FDA says it explained issues early on for Corcept's rejected Cushing's syndrome drug
生命科学资讯
生物技术与制药领域的最新动态
Bitterroot回归临床前生物技术领域，专注CD47靶点，同时CEO离职。
Bitterroot reverts to preclinical biotech in CD47 as CEO leaves
欧洲药品管理局人用药品委员会反对礼来Mounjaro用于心衰治疗，支持诺和诺德Kayshild。
CHMP opposes Lilly’s Mounjaro in heart failure, backs Novo’s Kayshild
Ultragenyx就罕见神经疾病基因疗法向FDA重新提交申请。
Ultragenyx resubmits gene therapy for rare neuro disease to FDA
Quince罕见病激素疗法失败，股价暴跌
Quince's steroid therapy for rare disease fails, shares tank
Janux任命首席营销官，此前与百时美施贵宝达成T细胞衔接器协议；Lexeo一批新任命出炉
Janux hires CMO after T cell engager deal with Bristol Myers; A batch of appointments at Lexeo
里德·乔布斯的癌症生物技术投资公司Yosemite瞄准3.5亿美元基金
Reed Jobs' cancer biotech investment firm Yosemite eyes $350M fund
阿斯利康以12亿美元收购石药集团长效减肥药。
AstraZeneca pays $1.2B for CSPC's long-acting obesity drugs
武田制药"预期"其畅销药Entyvio将进入医保谈判。
Takeda 'anticipated' Medicare negotiations for top seller Entyvio
武田制药候任CEO表示，不赞成特朗普的最惠国待遇协议。
Takeda is ‘not in favor’ of Trump’s MFN deals, CEO-designate says
白宫推迟原定特朗普处方药计划发布会
White House postpones planned TrumpRx launch event
赛诺菲疫苗业务受挫，誓言坚守承诺不动摇。
Sanofi vows to stay committed to vaccines as portfolio takes a hit
药房初创企业的命运多舛
The disrupted fate of pharmacy startups
赛诺菲削减研发管线；Breakthru Medicine融资6000万美元
Sanofi's pipeline cuts; Breakthru Medicine raises $60M
峰会制药PD-1xVEGF双特异性药物获11月PDUFA日期。
Summit gets November PDUFA date for its PD-1xVEGF bispecific
特朗普拟提高对韩征税；西格弗里德公司扩大业务。
Trump looks to raise South Korea levies; Siegfried expands
Agomab预计通过IPO筹集1.82亿美元，以构建其纤维化药物管线。
Agomab anticipates $182M IPO as it builds fibrosis pipeline
阿斯利康投资150亿美元押注中国，扩大制造与研发规模。
AstraZeneca makes $15B bet on China to expand manufacturing and R&D
赛诺菲称其150亿欧元交易预算及研发投入有望缓解Dupixent专利悬崖压力。
Sanofi says its €15B dealmaking budget, R&D spend should help ease looming Dupixent patent cliff
礼来成为旗舰公司Repertoire的新自身免疫合作伙伴。
Flagship's Repertoire gets another autoimmune partner in Lilly